The Coapsys device to treat functional mitral regurgitation: in vivo long-term canine study

Inoue, Masahiro; McCarthy, Patrick M.; Popović, Zoran B.; Doi, Kazuyoshi; Schenk, Soren; Nemeh, Hassan; Ootaki, Yoshio; Kopcak, Michael W.; Dessoffy, Raymond; Thomas, James D.; Fukamachi, Kiyotaka

doi:10.1016/j.jtcvs.2003.12.005

Cited by 45 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Repositioning of the posteromedial papillary muscle has been attempted externally 27 and internally 28 in animal models, and the Coapsys system is currently part of a clinical trial. 29 Hvass et al 30 described their clinical experience with moderately undersized annuloplasty and using a Gore-Tex tube to reapproximate the posterior and anterior papillary muscles in 10 patients with severe ischemic mitral regurgitation. The "tenting effect" was reduced and valve competence was achieved in most patients.…”

Section: Discussionmentioning

confidence: 99%

Initial Results of Posterior Leaflet Extension for Severe Type IIIb Ischemic Mitral Regurgitation

et al. 2009

View full text Add to dashboard Cite

Background-Management of severe ischemic mitral regurgitation remains difficult with disappointing early and intermediate-term surgical results of valve repair. Methods and Results-Forty-four patients with severe (4ϩ) Carpentier type IIIb ischemic mitral regurgitation underwent mitral valve repair, with or without surgical revascularization, by posterior leaflet extension with a patch of bovine pericardium and a remodeling annuloplasty. Serial echocardiography was performed preoperatively, intraoperatively, and postoperatively to assess mitral valve competence. The postoperative functional status of patients was assessed. The average Parsonnet score was 38Ϯ13. Thirty-day mortality was 11%, and late mortality was 14%. Mean follow-up was 38 months. The actuarial freedom from moderate or severe recurrent mitral regurgitation was 90% at 2 years, whereas 90% of patients were in New York Heart Association class I at 2 years. Conclusion-Posterior

show abstract

Section: Discussionmentioning

confidence: 99%

Initial Results of Posterior Leaflet Extension for Severe Type IIIb Ischemic Mitral Regurgitation

et al. 2009

View full text Add to dashboard Cite

show abstract

“…McCarthy's Coapsys device spans the LV with a reinforced suture that hoists a small pad at the posterior base anteriorly toward the right ventricular free wall. 81 The localized LV compression and need for anterior attachment without coronary or right ventricular compromise merit exploration.…”

Section: Therapymentioning

confidence: 99%

Ischemic Mitral Regurgitation on the Threshold of a Solution

2005

View full text Add to dashboard Cite

“…In experimental models, Liel-Cohen [44], Hung and Levine [45] have demonstrated that both infarct plication with sutures and an epicardial left ventricular patch can alter left ventricular geometry, reverse leaflet tenting, and reduce IMR. Clinical experience demonstrates that direct papillary muscle repositioning [46] and the Coapsys device [47] reduce the grade of IMR. In addition, external constraint may have a role in the management of patients with left ventricular dysfunction and IMR [48,49].…”

Section: Novel Repair Techniquesmentioning

confidence: 99%

Is ischemic mitral regurgitation an indication for surgical repair or replacement?

Gillinov

2006

Heart Fail Rev

View full text Add to dashboard Cite

Ischemic mitral regurgitation (IMR) is common in patients with coronary artery disease. While it is well-known that IMR exerts a graded effect upon survival-the greater the degree of IMR, the lower the survival-the indications for surgical treatment and the choice of surgical procedure (repair versus replacement) are controversial. In patients with mild to moderate IMR, the benefit of a mitral valve procedure has not been demonstrated, and surgical practice varies. In patients with severe IMR, mitral valve surgery is the norm, but guidelines for choosing between valve repair and valve replacement do not exist. Furthermore, the survival impact of mitral valve surgery in patients with severe IMR is uncertain. When patients with severe IMR undergo mitral valve surgery, undersized annuloplasty results in durable repair in 70% to 85% of cases. Newly-developed adjunctive repair techniques may further improve results. Currently, mitral valve repair is the procedure of choice in the majority of patients having surgery for severe IMR. However, the most severely ill patients and those with certain echocardiographic characteristics (e.g. severe bileaflet tethering) should be treated with bioprosthetic mitral valve replacement rather than repair.

show abstract

The Coapsys device to treat functional mitral regurgitation: in vivo long-term canine study

Abstract: The Coapsys device consistently and chronically reduced functional mitral regurgitation. This device is in clinical trials in the United States.

Cited by 45 publications

References 22 publications

Initial Results of Posterior Leaflet Extension for Severe Type IIIb Ischemic Mitral Regurgitation

Initial Results of Posterior Leaflet Extension for Severe Type IIIb Ischemic Mitral Regurgitation

Ischemic Mitral Regurgitation on the Threshold of a Solution

Is ischemic mitral regurgitation an indication for surgical repair or replacement?

Contact Info

Product

Resources

About